Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by Bridges Investment Management Inc.

Bridges Investment Management Inc. increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 111.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,509 shares of the medical equipment provider's stock after buying an additional 13,439 shares during the period. Bridges Investment Management Inc.'s holdings in Lantheus were worth $2,490,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Summit Securities Group LLC acquired a new position in shares of Lantheus during the fourth quarter worth $37,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 68.2% during the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 381 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Lantheus by 117.7% during the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after buying an additional 633 shares during the last quarter. 1620 Investment Advisors Inc. purchased a new stake in shares of Lantheus during the fourth quarter valued at $125,000. Finally, GAMMA Investing LLC grew its holdings in shares of Lantheus by 29.3% during the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock valued at $128,000 after buying an additional 298 shares during the last quarter. Institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

LNTH has been the topic of several recent research reports. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. B. Riley lowered their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Finally, Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lantheus presently has an average rating of "Buy" and a consensus price target of $130.50.

Lantheus Price Performance

LNTH stock traded up $0.34 during mid-day trading on Thursday, reaching $83.83. The company's stock had a trading volume of 814,865 shares, compared to its average volume of 1,001,940. The stock has a market cap of $5.80 billion, a PE ratio of 23.82 and a beta of 0.12. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a fifty-two week low of $73.11 and a fifty-two week high of $126.89. The company's 50 day moving average is $81.25 and its two-hundred day moving average is $90.06.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm's revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.69 EPS. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at $24,481,879.50. This trade represents a 7.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.